US 12,403,131 B2
Afabicin formulation, method for making the same and uses thereof
Marie Decrette, Publier (FR); Aude Anne-Laure Colin, Publier (FR); and Sebastien Chabaud, Riehen (CH)
Assigned to Debiopharm International S.A., Lausanne (CH)
Appl. No. 17/430,616
Filed by Debiopharm International S.A., Lausanne (CH)
PCT Filed Feb. 14, 2020, PCT No. PCT/EP2020/053882
§ 371(c)(1), (2) Date Aug. 12, 2021,
PCT Pub. No. WO2020/165407, PCT Pub. Date Aug. 20, 2020.
Claims priority of application No. 19157255 (EP), filed on Feb. 14, 2019.
Prior Publication US 2022/0142993 A1, May 12, 2022
Int. Cl. A61K 31/437 (2006.01); A61K 9/20 (2006.01); A61K 31/40 (2006.01)
CPC A61K 31/437 (2013.01) [A61K 9/20 (2013.01); A61K 31/40 (2013.01)] 18 Claims
 
1. A solid pharmaceutical composition in the form of a unit dose comprising Afabicin or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, characterized in that the composition contains a histidine compound,
wherein the composition shows more rapid dissolution compared with a composition lacking histidine comprising the same components.